缺氧诱导因子-1α参与肝纤维化形成机制研究进展

doi:10.3969/j.issn.1672-5069.2021.01.038

摘要/Abstract

摘要： 目的肝纤维化是一种由于反复肝损伤而导致肝组织细胞外基质过多沉积导致的疾病。缺氧损伤为肝损伤的一部分,缺氧诱导因子-1α(HIF-1α)是响应缺氧应激的关键转录因子,在肝纤维化组织和活化的肝星状细胞(HSC)表达显著增加。目前,通过对大量HIF-1α依赖性基因和信号通路的研究,确认这些基因及其通路的变化参与肝纤维化发展过程,并可能在肝纤维化发生发展过程中起关键作用。本文综述了HIF-1α相关的信号通路参与肝纤维化发展的相关机制,并对上游影响HIF-1α合成和降解的相关信号通路进行了阐述,为其作为新型治疗靶点的可能潜力提供依据。

关键词: 肝纤维化, 缺氧诱导因子-1α, 治疗靶点

Abstract: Objective Liver fibrosis is caused by excessive deposition of extracellular matrix in liver tissues due to repeated liver injuries and hypoxia injury is a part of liver injury. Hypoxia inducible factor-1 α (HIF-1α) is a key transcription factor in response to hypoxia stress, and its expression in liver fibrotic tissues and activated HSCs is significantly increased. At present, a number of HIF-1α dependent genes and related signaling pathways have been studied to confirm that the changes of these genes and pathways are related to the development of liver fibrosis, suggesting that HIF-1α may play a key role in liver fibrosis. In this review, the mechanism of HIF-1α-related signaling pathway in the development of liver fibrosis and the synthesis and degradation of HIF-1α from the upstream are described.

Key words: Liver fibrosis, Hypoxia inducible factor-1α, Therapeutic target

刘瑞清(综述), 袁小澎(审校). 缺氧诱导因子-1α参与肝纤维化形成机制研究进展[J]. 实用肝脏病杂志, 2021, 24(1): 145-148.

Liu Ruiqing,Yuan Xiaopeng. Mechanism of hypoxia inducible factor-1α involving in liver fibrosis[J]. Journal of Practical Hepatology, 2021, 24(1): 145-148.

参考文献

[1] Roth K J, Copple B L. Role of hypoxia-inducible factors in the development of liver fibrosis. Cell Mol Gastroenterol Hepatol, 2015, 1(6): 589-597.
[2] Bataller R, Brenner D A. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis, 2001, 21(3): 437-451.
[3] Friedman S L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev, 2008, 88(1): 125-172.
[4] Moon J O, Welch T P, Gonzalez F J, et al. Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice. Am J Physiol Gastrointest Liver Physiol, 2009, 296(3): G582-G592.
[5] Nath B, Szabo G. Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. Hepatology, 2012, 55(2): 622-633.
[6] 杜静,赵秋,谷华,等. 缺氧诱导因子-1α及其靶基因在人肝癌HepG2细胞中的表达和意义. 中华肝脏病杂志, 2006,12(8): 607-609.
[7] Sparkenbaugh E M, Saini Y, Greenwood K K, et al. The role of hypoxia-inducible factor-1alpha in acetaminophen hepatotoxicity. J Pharmacol Exp Ther, 2011, 338(2): 492-502.
[8] Copple B L, Bai S, Burgoon L D, et al. Hypoxia-inducible factor-1alpha regulates the expression of genes in hypoxic hepatic stellate cells important for collagen deposition and angiogenesis. Liver Int, 2011, 31(2): 230-244.
[9] Yang F, Luo L, Zhu Z D, et al. Chlorogenic acid inhibits liver fibrosis by blocking the miR-21-regulated TGF-beta1/Smad7 signaling pathway in vitro and in vivo. Front Pharmacol, 2017, 8: 929.
[10] Carmeliet P. Angiogenesis in life, disease and medicine. Nature, 2005, 438(7070): 932-936.
[11] 姚登福,孟宪镛. 肝细胞癌变过程中血管内皮生长因子异常表达及其机制的研究进展. 中华肝脏病杂志, 2001,9(3): 187-188.
[12] Qu K, Yan Z, Wu Y, et al. Transarterial chemoembolization aggravated peritumoral fibrosis via hypoxia-inducible factor-1alpha dependent pathway in hepatocellular carcinoma. J Gastroenterol Hepatol, 2015, 30(5): 925-932.
[13] Chen D, Tian W, Li Y, et al. Osteoblast-specific transcription factor Osterix (Osx) and HIF-1alpha cooperatively regulate gene expression of vascular endothelial growth factor (VEGF). Biochem Biophys Res Commun, 2012, 424(1): 176-181.
[14] Weijts B G, Bakker W J, Cornelissen P W, et al. E2F7 and E2F8 promote angiogenesis through transcriptional activation of VEGFA in cooperation with HIF1. EMBO J, 2012, 31(19): 3871-3884.
[15] Carbajo-Pescador S, Ordonez R, Benet M, et al. Inhibition of VEGF expression through blockade of Hif1alpha and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer, 2013, 109(1): 83-91.
[16] Li Z, Ding Q, Ling L P, et al. Metformin attenuates motility, contraction, and fibrogenic response of hepatic stellate cells in vivo and in vitro by activating AMP-activated protein kinase. World J Gastroenterol, 2018, 24(7): 819-832.
[17] Zhang F, Hao M, Jin H, et al. Canonical hedgehog signalling regulates hepatic stellate cell-mediated angiogenesis in liver fibrosis. Br J Pharmacol, 2017, 174(5): 409-423.
[18] Gao J H, Wen S L, Feng S, et al. Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats. Angiogenesis, 2016, 19(4): 501-511.
[19] Ni H M, Williams J A, Yang H, et al. Targeting autophagy for the treatment of liver diseases. Pharmacol Res, 2012, 66(6): 463-474.
[20] Deng J, Huang Q, Wang Y, et al. Hypoxia-inducible factor-1alpha regulates autophagy to activate hepatic stellate cells. Biochem Biophys Res Commun, 2014, 454(2): 328-334.
[21] Zhou X, Sun H, Chen H, et al. Hypoxia induces trimethylated H3 lysine 4 by inhibition of JARID1A demethylase. Cancer Res, 2010, 70(10): 4214-4221.
[22] Hong F, Wan L, Liu J, et al. Histone methylation regulates Hif-1 signaling cascade in activation of hepatic stellate cells. FEBS Open Bio, 2018, 8(3): 406-415.
[23] Ara A I, Xia M, Ramani K, et al. S-adenosylmethionine inhibits lipopolysaccharide-induced gene expression via modulation of histone methylation. Hepatology, 2008, 47(5): 1655-1666.
[24] Laplante M, Sabatini D M. mTOR signaling in growth control and disease. Cell, 2012, 149(2): 274-293.
[25] Zhao Y, Ma X, Wang J, et al. Paeoniflorin alleviates liver fibrosis by inhibiting HIF-1alpha through mTOR-dependent pathway. Fitoterapia, 2014, 99: 318-327.
[26] Rius J, Guma M, Schachtrup C, et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature, 2008, 453(7196): 807-811.
[27] Moczydlowska J, Miltyk W, Hermanowicz A, et al. HIF-1 alpha as a key factor in bile duct ligation-induced liver fibrosis in rats. J Invest Surg, 2017, 30(1): 41-46.
[28] Sutton K M, Hayat S, Chau N M, et al. Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1. Oncogene, 2007, 26(27): 3920-3929.
[29] Wang Y, Huang Y, Guan F, et al. Hypoxia-inducible factor-1alpha and MAPK co-regulate activation of hepatic stellate cells upon hypoxia stimulation. PLoS One, 2013, 8(9): e74051.
[30] Copple B L, Kaska S, Wentling C. Hypoxia-inducible factor activation in myeloid cells contributes to the development of liver fibrosis in cholestatic mice. J Pharmacol Exp Ther, 2012, 341(2): 307-316.
[31] Zhao Y, Ma X, Wang J, et al. Curcumin protects against CCl₄-induced liver fibrosis in rats by inhibiting HIF-1alpha through an ERK-dependent pathway. Molecules, 2014, 19(11): 18767-18780.
[32] Chouchani E T, Pell V R, Gaude E, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature, 2014, 515(7527): 431-435.
[33] She L, Xu D, Wang Z, et al. Curcumin inhibits hepatic stellate cell activation via suppression of succinate-associated HIF-1alpha induction. Mol Cell Endocrinol, 2018, 476: 129-138.
[34] Jaakkola P, Mole D R, Tian Y M, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science, 2001, 292(5516): 468-472.
[35] Mills E L, Kelly B, Logan A, et al. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell, 2016, 167(2): 457-470.
[36] Wang J, Lu Z, Xu Z, et al. Reduction of hepatic fibrosis by overexpression of von Hippel-Lindau protein in experimental models of chronic liver disease. Sci Rep, 2017, 7: 41038.
[37] Zhang C, Bian M, Chen X, et al. Oroxylin A prevents angiogenesis of LSECs in liver fibrosis via inhibition of YAP/HIF-1alpha signaling. J Cell Biochem, 2018, 119(2): 2258-2268.
[38] Deleve L D. Liver sinusoidal endothelial cells in hepatic fibrosis. Hepatology, 2015, 61(5): 1740-1746.
[39] Ma B, Chen Y, Chen L, et al. Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase. Nat Cell Biol, 2015, 17(1): 95-103.